Paper Details

  1. Home
  2. Paper Details

Rofecoxib for the treatment of rheumatoid arthritis.

Author: FidanD, FrankishR, GarnerS, JuddM, TowheedT, TugwellP, WellsG

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This review assessed the efficacy and toxicity of rofecoxib for treating rheumatoid arthritis. Two randomized controlled trials were included. Rofecoxib demonstrated a greater degree of efficacy than placebo, while having a comparable safety profile. Rofecoxib also demonstrated a similar degree of efficacy as naproxen, but with a significantly lower rate of ulceration and gastrointestinal bleeding. However, rofecoxib was associated with a greater risk for myocardial infarction, but the exact significance and pathophysiology of this possible relationship is unclear.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Rheumatoid arthritis (RA) is a systemic auto-immune disorder, in which the synovial lining of many joints and tendon sheaths are persistently inflamed. OBJECTIVES: To assess the efficacy and toxicity of rofecoxib for treating RA. SEARCH STRATEGY: We searched the following electronic da...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD003685

データ提供：米国国立医学図書館（NLM）

Rofecoxib for Rheumatoid Arthritis: Efficacy and Safety in Focus

Rheumatoid arthritis (RA), a chronic inflammatory disease, continues to be a significant health concern. This study evaluates the efficacy and toxicity of rofecoxib, a COX-2 inhibitor, in treating RA. The authors conducted a systematic review of randomized controlled trials to assess the drug's effectiveness and safety profile.

A Balancing Act: Assessing the Benefits and Risks of Rofecoxib

The review found that rofecoxib demonstrated greater efficacy than placebo in treating RA, with a significant improvement in disease activity. However, it also highlighted a potential increased risk of cardiovascular events, including myocardial infarction, associated with rofecoxib use. The authors underscore the importance of weighing the benefits and risks carefully before prescribing this medication.

Navigating the Desert of RA Treatment: Choosing the Right Path

This research provides valuable information for clinicians and patients regarding the use of rofecoxib in RA. It emphasizes the need for a careful assessment of individual patient risks and a collaborative approach to treatment decisions. It's like navigating a desert where the journey is long and the terrain is challenging, but with the right knowledge and guidance, we can find a path towards better health.

Dr. Camel's Conclusion

This study provides a comprehensive assessment of the efficacy and safety of rofecoxib in treating rheumatoid arthritis. The findings highlight the importance of a careful evaluation of individual patient risks and a collaborative approach to treatment decisions, ensuring that the benefits of medication outweigh the potential risks.

Date :
  1. Date Completed 2002-09-24
  2. Date Revised 2020-05-11
Further Info :

Pubmed ID

12137705

DOI: Digital Object Identifier

10.1002/14651858.CD003685

Related Literature

Article Analysis
・Effective treatment of rheumatoid arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.